WO2000047236A8 - Matrices for drug delivery and methods for making and using the same - Google Patents

Matrices for drug delivery and methods for making and using the same

Info

Publication number
WO2000047236A8
WO2000047236A8 PCT/US2000/003754 US0003754W WO0047236A8 WO 2000047236 A8 WO2000047236 A8 WO 2000047236A8 US 0003754 W US0003754 W US 0003754W WO 0047236 A8 WO0047236 A8 WO 0047236A8
Authority
WO
WIPO (PCT)
Prior art keywords
matrices
making
methods
same
drug delivery
Prior art date
Application number
PCT/US2000/003754
Other languages
French (fr)
Other versions
WO2000047236A1 (en
Inventor
John W Babich
Grant Bonavia
Jon Zubieta
Original Assignee
Biostream Inc
John W Babich
Grant Bonavia
Jon Zubieta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostream Inc, John W Babich, Grant Bonavia, Jon Zubieta filed Critical Biostream Inc
Priority to IL13899000A priority Critical patent/IL138990A0/en
Priority to CA2328614A priority patent/CA2328614C/en
Priority to JP2000598187A priority patent/JP4812167B2/en
Priority to AU27599/00A priority patent/AU772153B2/en
Publication of WO2000047236A1 publication Critical patent/WO2000047236A1/en
Publication of WO2000047236A8 publication Critical patent/WO2000047236A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica

Abstract

In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L-amino acid decarboxylase is encapsulated and implanted in the brain to convert L-dopa to dopamine for treatment of Parkinson's disease.
PCT/US2000/003754 1999-02-12 2000-02-14 Matrices for drug delivery and methods for making and using the same WO2000047236A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL13899000A IL138990A0 (en) 1999-02-12 2000-02-14 Matrices for drug delivery and methods for making and using the same
CA2328614A CA2328614C (en) 1999-02-12 2000-02-14 Matrices for drug delivery and methods for making and using the same
JP2000598187A JP4812167B2 (en) 1999-02-12 2000-02-14 Drug transport matrix and methods for making and using the same
AU27599/00A AU772153B2 (en) 1999-02-12 2000-02-14 Matrices for drug delivery and methods for making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11982899P 1999-02-12 1999-02-12
US60/119,828 1999-02-12

Publications (2)

Publication Number Publication Date
WO2000047236A1 WO2000047236A1 (en) 2000-08-17
WO2000047236A8 true WO2000047236A8 (en) 2001-04-19

Family

ID=22386633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003754 WO2000047236A1 (en) 1999-02-12 2000-02-14 Matrices for drug delivery and methods for making and using the same

Country Status (6)

Country Link
US (4) US6395299B1 (en)
JP (1) JP4812167B2 (en)
AU (1) AU772153B2 (en)
CA (1) CA2328614C (en)
IL (1) IL138990A0 (en)
WO (1) WO2000047236A1 (en)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764690B2 (en) * 1996-05-29 2004-07-20 Delsitech Oy Dissolvable oxides for biological applications
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6896874B2 (en) * 1998-05-26 2005-05-24 Wisconsin Alumni Research Foundation MR-signal emitting coatings
US6361759B1 (en) * 1998-05-26 2002-03-26 Wisconsin Alumni Research Foundation MR signal-emitting coatings
US7118921B1 (en) * 1999-06-24 2006-10-10 Mcmaster University Incorporation and applications of biomolecular interactions within a carrier
AU2001248129A1 (en) * 2000-04-17 2001-10-30 Befa Handelsgesellschaft M.B.H. Method for determining the concentration of carnitine in fluids
EP1335693A2 (en) 2000-04-21 2003-08-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6592860B1 (en) * 2000-05-30 2003-07-15 Soluble Systems, Llc Composition and applicator for topical substance delivery
HUP0401300A3 (en) * 2001-01-18 2005-06-28 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
WO2002080885A1 (en) * 2001-04-03 2002-10-17 University Of Florida Detoxification and decontamination using nanotechnology therapy
US6977171B1 (en) 2001-04-03 2005-12-20 University Of Florida Detoxification and decontamination using nanotechnology therapy
GB0116853D0 (en) 2001-07-10 2001-09-05 Torsana Diabetes Diagnostics A Optical sensor containing particles for in SITU measurement of analytes
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2005524657A (en) * 2002-02-27 2005-08-18 ファーメイン， エルティーディー． Compositions for delivering therapeutic agents and other substances, and methods of making and using said compositions
GB0205772D0 (en) * 2002-03-12 2002-04-24 Gill Steven S Catheter
EP1534295A4 (en) * 2002-07-17 2009-08-05 Chemgenex Pharmaceuticals Inc Formulations and methods of administration of cephalotaxines, including homoharringtonine
EP1575554A1 (en) * 2002-12-06 2005-09-21 Monosolrx Llc Thin film delivery systems for volatile decongestants
ITMI20022777A1 (en) * 2002-12-27 2004-06-28 Altergon Sa PHARMACEUTICAL FORMULATIONS FOR THYROID HORMONES AND PROCEDURES FOR THEIR OBTAINING.
WO2004081222A2 (en) 2003-03-14 2004-09-23 Sol-Gel Technologies Ltd. Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
CA2520312C (en) * 2003-03-26 2013-06-18 Egalet A/S Matrix compositions for controlled delivery of drug substances
ATE495732T1 (en) 2003-03-26 2011-02-15 Egalet As CONTROLLED RELEASE MORPHINE SYSTEM
US20040234962A1 (en) * 2003-05-02 2004-11-25 Javier Alarcon Multicoated or multilayer entrapment matrix for protein biosensor
DE10321082A1 (en) * 2003-05-09 2004-11-25 Basf Ag Process for the preparation of a hydroxylation catalyst and its use
US7067169B2 (en) * 2003-06-04 2006-06-27 Chemat Technology Inc. Coated implants and methods of coating
JP2007500590A (en) 2003-07-31 2007-01-18 ゾル−ゲル テクノロジーズ エルティーディー． Microcapsule filled with active ingredient and method for producing the same
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US20050095174A1 (en) * 2003-10-31 2005-05-05 Wolf David E. Semipermeable sensors for detecting analyte
US20050095690A1 (en) * 2003-10-31 2005-05-05 Naik Rajesh R. Entrapment of biomolecules and inorganic nanoparticles by biosilicification
US7642077B2 (en) * 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
US8097269B2 (en) * 2004-02-18 2012-01-17 Celonova Biosciences, Inc. Bioactive material delivery systems comprising sol-gel compositions
US7981441B2 (en) * 2004-02-18 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Drug delivery systems using mesoporous oxide films
GB0420016D0 (en) * 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
CA2580679A1 (en) * 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
US8435948B2 (en) 2004-09-29 2013-05-07 Mount Sinai School Of Medicine Of New York University Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
EP1838289B1 (en) 2004-12-20 2017-12-13 Australian Nuclear Science And Technology Organisation Controlled release of biological entities
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
KR101158162B1 (en) 2005-08-02 2012-06-19 솔-겔 테크놀로지스 리미티드 Metal oxide coating of water insoluble ingredients
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders
EP1942731A2 (en) 2005-09-27 2008-07-16 Sol-Gel Technologies Ltd. Methods for crop protection
EP1962914B1 (en) 2005-11-14 2019-02-27 Biomet 3i, LLC Deposition of discrete nanoparticles on an implant surface
DE102006012244A1 (en) * 2005-11-16 2007-05-31 Pro Natura Gesellschaft für gesunde Ernährung mbH New 5-D-fructose dehydrogenase, optionally in combination with invertase, maltase and/or glucose isomerase, useful in therapy or diagnosis of disorders of fructose metabolism, including fructose intolerance
DE102006013624B4 (en) * 2005-11-23 2012-03-15 Pro Natura Gesellschaft für gesunde Ernährung mbH Means for use in fructose intolerance
CA2669431C (en) * 2005-11-16 2019-04-23 Pro Natura Gesellschaft Fuer Gesunde Ernaehrung Mbh Agent for use in the case of fructose intolerance
AU2013273733B2 (en) * 2005-11-16 2015-12-24 Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh Agent for use in the case of fructose intolerance
AU2013211517B2 (en) * 2005-11-23 2016-06-30 Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
WO2007059956A1 (en) * 2005-11-23 2007-05-31 Pro Natura Gesellschaft für gesunde Ernährung mbH Agent for use in the case of disorders of blood sugar metabolism, including diabetes
DE102006013623A1 (en) * 2005-11-23 2007-05-24 Pro Natura Gesellschaft für gesunde Ernährung mbH New 5-D-fructose-dehydrogenase useful e.g. as a medicament, food, dietetic food, food additives or a balanced diet and for the therapy of adiposity
US20090060956A1 (en) * 2005-11-23 2009-03-05 Daniel Henry Wyrobnik Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
DE102005056103A1 (en) * 2005-11-23 2007-05-24 Pro Natura Gesellschaft für gesunde Ernährung mbH Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20070156042A1 (en) * 2005-12-30 2007-07-05 Orhan Unal Medical device system and method for tracking and visualizing a medical device system under MR guidance
US8457712B2 (en) * 2005-12-30 2013-06-04 Wisconsin Alumni Research Foundation Multi-mode medical device system and methods of manufacturing and using same
ES2390314T3 (en) * 2006-02-24 2012-11-08 Medibeacon Development, Llc Optical agents for use in surgery
US10278917B2 (en) 2006-04-14 2019-05-07 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US8920821B2 (en) 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
EP2020987B1 (en) * 2006-06-06 2013-10-30 Universidad Autónoma Metropolitana Sol-gel nanostructured titania reservoirs for use in the controlled release of drugs in the central nervous system and method of synthesis
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008036449A2 (en) * 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
DE102006038629A1 (en) * 2006-08-17 2008-02-21 Dr. Suwelack Skin & Health Care Ag Stabilized active ingredient composition
CA2667890C (en) 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
US8532742B2 (en) * 2006-11-15 2013-09-10 Wisconsin Alumni Research Foundation System and method for simultaneous 3DPR device tracking and imaging under MR-guidance for therapeutic endovascular interventions
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20080183070A1 (en) * 2007-01-29 2008-07-31 Wisconsin Alumni Research Foundation Multi-mode medical device system with thermal ablation capability and methods of using same
MX2009008250A (en) 2007-02-01 2009-08-27 Sol Gel Technologies Ltd Compositions for topical application comprising a peroxide and retinoid.
EP2118208B1 (en) 2007-02-01 2019-10-09 Sol-Gel Technologies Ltd. Method for preparing particles comprising metal oxide coating
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
DE102007008664B4 (en) 2007-02-20 2021-07-29 Vitacare Gmbh & Co. Kg Means for use in fructose intolerance
US8412306B2 (en) * 2007-02-28 2013-04-02 Wisconsin Alumni Research Foundation Voltage standing wave suppression for MR-guided therapeutic interventions
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
KR100860958B1 (en) * 2007-08-08 2008-09-30 전남대학교산학협력단 A multi-channel bioreactor with the immobillization of optical sensing membrane
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
JP2009044997A (en) * 2007-08-20 2009-03-05 Sony Corp Method for coating bod (bilirubin oxidase)
WO2009088385A1 (en) * 2008-01-04 2009-07-16 Capricorn Pharma Inc. Resin-complex granulation for water-soluble drugs and associated methods
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
JP5806466B2 (en) * 2008-01-28 2015-11-10 バイオメット・３アイ・エルエルシー Implant surface with improved hydrophilicity
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
GB0805279D0 (en) * 2008-03-20 2008-04-30 Univ Nottingham Trent Food supplement
US9114125B2 (en) 2008-04-11 2015-08-25 Celonova Biosciences, Inc. Drug eluting expandable devices
DE102008033327A1 (en) * 2008-07-16 2010-01-21 Bayer Innovation Gmbh Silica sol material having at least one therapeutically active agent for the production of biodegradable and / or resorbable silica gel materials for human medicine and / or medical technology
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
EP2151466A1 (en) * 2008-08-01 2010-02-10 SiNatur GmbH Biologically active silicic acid
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP2246065A1 (en) * 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
WO2011097335A2 (en) 2010-02-04 2011-08-11 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US8641418B2 (en) 2010-03-29 2014-02-04 Biomet 3I, Llc Titanium nano-scale etching on an implant surface
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US20120136416A1 (en) * 2010-11-19 2012-05-31 President And Fellows Of Harvard College Caged Neuropeptides: modulation and measurement of synapse and signaling activity; and methods for drug evaluation, pharmaceuticals preparation and treatment
CA2820841C (en) * 2010-12-17 2018-10-23 Eyesense Ag Competitive biosensor having elevated sensitivity
CA2827559A1 (en) * 2011-02-22 2012-08-30 Regents Of The University Of Minnesota Silica encapsulated biomaterials
US9427408B2 (en) 2011-11-07 2016-08-30 Lisa Kasinkas Silica-matrix forming compositions, materials formed therefrom, and methods of using the same
US9131995B2 (en) 2012-03-20 2015-09-15 Biomet 3I, Llc Surface treatment for an implant surface
CA2869568A1 (en) * 2012-04-06 2013-10-10 Akermin, Inc. Polysilicate-polysilicone enzyme immobilization materials
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
US9534236B2 (en) 2013-03-08 2017-01-03 Regents Of The University Of Minnesota Membranes for wastewater-generated energy and gas
WO2014182054A1 (en) * 2013-05-07 2014-11-13 고려대학교 산학협력단 Recombinant microorganism metabolizing 3,6-anhydride-l-galactose and a use thereof
US9593080B1 (en) 2014-06-11 2017-03-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Triazabutadienes as cleavable cross-linkers
US10047061B2 (en) 2014-06-11 2018-08-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Water-soluble triazabutadienes
US10125105B2 (en) 2014-06-11 2018-11-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Triazabutadienes as cleavable cross-linkers
US10035719B2 (en) 2014-10-15 2018-07-31 Regents Of The University Of Minnesota System and membrane for wastewater-generated energy and gas
US10954195B2 (en) 2015-08-11 2021-03-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted triazenes protected from degradation by carboxylation of N1
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CA3022840A1 (en) 2016-05-05 2017-11-09 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11339129B2 (en) 2016-07-29 2022-05-24 Arizona Board of Regents on behalf of the University of Arizon Triazabutadienes as cleavable cross-linkers
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
CN110343690B (en) 2018-04-05 2021-12-07 宁波酶赛生物工程有限公司 Decarboxylase polypeptide and application thereof in preparation of tyramine and dopamine
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN109022413A (en) * 2018-08-10 2018-12-18 暨南大学 A kind of monoamine oxidase A microreactor and its preparation method and application
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery
CN112716895A (en) * 2020-12-18 2021-04-30 济南大学 Andrographolide drug-loaded micelle of Pluronic F127 modified based on phenylbutyric acid and preparation method thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54143588A (en) * 1978-04-25 1979-11-08 Unitika Ltd Preparation of sterilized, immobilized enzyme
JPS60120987A (en) * 1983-12-05 1985-06-28 Kikkoman Corp Production of immobilized microbial cell or enzyme
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US5510254A (en) * 1986-04-18 1996-04-23 Advanced Tissue Sciences, Inc. Three dimensional cell and tissue culture system
CA1339955C (en) 1986-10-14 1998-07-14 Richard Eugene Heiney Process for transforming a human insulin precursor to human insulin
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5786216A (en) 1987-11-17 1998-07-28 Cytotherapeutics, Inc. Inner-supported, biocompatible cell capsules
US5773286A (en) 1987-11-17 1998-06-30 Cytotherapeutics, Inc. Inner supported biocompatible cell capsules
JP2688596B2 (en) * 1988-08-05 1997-12-10 株式会社ワイエムシィ Enzyme-immobilized column packing material
US5665589A (en) 1988-12-14 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Human liver epithelial cell lines
US5770416A (en) 1989-05-26 1998-06-23 Upfront Chromatography A/S Permeable hollow particles having an outer shell of mechanically rigid porous material
US5308495A (en) 1990-01-23 1994-05-03 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Chromatography processes using doped sol gel glasses as chromatographic media
US5371018A (en) 1990-01-23 1994-12-06 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Qualitative and quantitative processes for reactive chemicals in liquids using doped sol-gel glasses
IL93134A (en) 1990-01-23 1997-11-20 Yissum Res Dev Co Doped sol-gel glasses for obtaining chemical interactions
DK165090D0 (en) * 1990-07-09 1990-07-09 Kem En Tec As CONLOMERATED PARTICLES
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5204369A (en) 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US5378232A (en) 1991-08-28 1995-01-03 Orion Therapeutic Systems, Inc. Injection/activation apparatus
JPH0587811A (en) * 1991-09-30 1993-04-06 Konica Corp Manufacture of carrier for fixing
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JPH06126134A (en) * 1992-10-13 1994-05-10 Osaka Gas Co Ltd Method for purification of nitrogen oxide in exhaust gas
US5693513A (en) * 1995-01-10 1997-12-02 Pope; Edward J. A. Encapsulation of living tissue cells in an organosilicon
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4342770A1 (en) 1993-12-15 1995-07-06 Boehringer Mannheim Gmbh Carrier-fixed enzymes
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5817327A (en) 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
JPH08131190A (en) * 1994-11-10 1996-05-28 New Japan Radio Co Ltd Biosensor
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5759539A (en) 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
SI0795334T1 (en) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Prodrugs for the treatment tumors and inflammatory diseases
JP2862509B2 (en) * 1996-05-28 1999-03-03 東洋電化工業株式会社 Carrier for lipase immobilization and immobilized lipase
EP1618896A3 (en) 1996-05-29 2010-07-14 DelSiTech Oy Dissolvable oxides for biological applications
US5849371A (en) * 1996-07-22 1998-12-15 Beesley; Dwayne Laser and laser-assisted free electron beam deposition apparatus and method
JP4061415B2 (en) * 1998-09-10 2008-03-19 東洋紡績株式会社 Immobilization carrier, immobilized enzyme preparation and production method thereof

Also Published As

Publication number Publication date
CA2328614C (en) 2012-06-26
US6395299B1 (en) 2002-05-28
US20070098807A1 (en) 2007-05-03
CA2328614A1 (en) 2000-08-17
IL138990A0 (en) 2001-11-25
JP4812167B2 (en) 2011-11-09
WO2000047236A1 (en) 2000-08-17
US7052913B2 (en) 2006-05-30
AU2759900A (en) 2000-08-29
AU772153B2 (en) 2004-04-08
US20030082238A1 (en) 2003-05-01
US20040241205A1 (en) 2004-12-02
JP2002536422A (en) 2002-10-29

Similar Documents

Publication Publication Date Title
WO2000047236A8 (en) Matrices for drug delivery and methods for making and using the same
Obeso et al. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease
UA29563C2 (en) Microcapsule for prolonged release of physiologically active peptide
AU1369297A (en) Medical implant
EA200300046A1 (en) QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION
WO2002004001A3 (en) A composition for the delivery of live cells and methods of use
WO2005000266A3 (en) Liposomal formulations comprising a combination of two or more active agents
DE69529054D1 (en) TARGETED ACTIVE SUBSTANCE SYSTEM, METHOD FOR THE PRODUCTION AND USE THEREOF
HK1061194A1 (en) Improved transdermal therapeutic system for the treatment of parkinson's disease
CA2319946A1 (en) Implant-supported dental prosthesis and a process for its production
EP1143950A3 (en) Topical application products
PT1317419E (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2005068498A3 (en) Human therapeutic cells secreting nerve growth factor
IT1307829B1 (en) DENTAL PROSTHESIS WITH MEANS FOR THE RELEASE OF DRUGS OR SPECIFIC FACTORS TO PREVENT THE ONset OF INFECTIONS AND / OR PROMOTE
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
IL150818A0 (en) Composition for intestinal delivery
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
CA2366841A1 (en) Tolperisone-containing pharmaceutical preparation for oral administration
YU68702A (en) Novel lhrh-antagonists, production and use thereof as medicament
MXPA04003506A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease.
CA2245370A1 (en) Production of pharmaceutical formulations for treatment of edema and venous disorders
BR0008739A (en) Controlled-release compositions of beta-histine
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
AU5277000A (en) Stimulating transport of glucose into animal tissue by the administration of pinitol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 27599/00

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2328614

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 138990

Country of ref document: IL

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 33/2000 UNDER (81) ADD "US"

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWG Wipo information: grant in national office

Ref document number: 27599/00

Country of ref document: AU